UNSPSC 51294403: Aripiprazole

This classification denotes an antipsychotic agent with the molecular formula C23H27Cl2N3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 82VFR53I78, chemically known as 7-(4-(4-(2,3-dichlorophenyl)-1-piperazinyl)butyloxy)-3,4-dihydro-2(1h)-quinolinone but generally known as aripiprazole, which bears US NIH Compound Identifier 60795. European Medicines Agency schedules Aripiprazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05564MIG.

UNSPSC 51294403 Aripiprazole is a Commodity code that nominally addresses a specific antipsychotic pharmaceutical, yet the recent state and local procurement activity tagged under it reflects a substantial mismatch. Seminole County, Florida's posted solicitation (IFB60459723LAS) seeks Naloxone and drug deactivation systems—opioid-reversal agents and harm-reduction equipment—rather than aripiprazole itself. The procurement structure is representative of how state and local health and social-services agencies use emergency-management and public-health purchasing vehicles to acquire medications and medical devices that support community health initiatives. Issuing bodies using this code tier include county government health departments and community health authorities, typically through competitive invitation for bid (IFB) processes that require electronic submission, unit-cost pricing, proof of workplace compliance (E-Verify, drug-free workplace certification), and standard commercial insurance.

The recent activity centers in Florida, specifically Seminole County's annual procurement of 1,900 units of naloxone and 800 safe drug deactivation systems with quarterly deliveries to the Seminole County Community Health Building in Sanford. The IFB posted June 30, 2026, with a response deadline of July 26, 2023 (note: date discrepancy in source), carries a two-year initial term with one-year renewal option and includes potential FEMA funding with attendant federal compliance requirements. The code shows limited recent relevant activity at the state and local level; the single opportunity identified is categorically distinct from the code's pharmaceutical scope, suggesting either misclassification in the source system or narrow deployment of this commodity code among state and local procurers. Firms evaluating pursuit should verify whether opportunities are actually aripiprazole-specific or whether jurisdictions are systematically using this code for broader pharmaceutical and medical-device acquisitions.